Recombinant Mouse IL-18 (without BSA)

  • Code # B004-5
  • Size 25 µg
  • Price
    $311.90
Specifications

Alternative Names

interleukin 18 (interferon-γ-inducing factor)

Background

Interleukin 18 (IL-18) is an 18-kDa cytokine which identified as a costimulatory factor for production of interferon-g (IFN-g) in response to toxic shock and shares functional similarities with IL-12. IL-18 is synthesized as a precursor 24-kDa molecule without a signal peptide and must be cleaved to produce an active molecule. IL-1 converting enzyme (ICE, Caspase-1) cleaves pro-IL-18 at aspartic acid in the P1 position, producing the mature, bioactive peptide that is readily released from the cells. It is reported that IL-18 is produced from Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells and murine diencephalon. IFN-g is produced by activated T or NK cells and plays critical roles in the defense against microbiral pathogens. IFN-g activates macrophages and enhances NK activity and B cell maturation, proliferation and Ig secretion. IFN-g also induces expression of MHC class I and II antigens and inhibits osteoclast activation. IL-18 acts on T helper type-1 (Th1) T cells and in combination with IL-12 strongly induces them to produce IFN-g. Pleiotropic effects of IL-18 have also been reported, such as, enhancement production of IFN-g and GM-CSF in peripheral blood mononuclear cells, production of Th1 cytokines, IL-2, GM-CSF and IFN-g in T cells, enhancement of Fas ligand expression by Th1 cells
  • Description:
    IL-18 Protein of 25 µg.
  • Formulation:
    Lyophilized in PBS containing 1%sucrose. Reconstitute in 250 μl of ice-cold distilled wateron ice.
  • Gene ID (Human):
  • Product Type:
    Cytokine
  • Research Area:
    Immunology
  • Short Description:
    IL-18 Protein.
  • Size:
    25 µg
  • Storage Temperature:
    -20°C. Please refer to datasheet for additional information
Citations
  1. Hirano Y et al. IL-18 is not therapeutic for neovascular age-related macular degeneration. Nat Med. 20, 1372-5 (2014),
  2. Iijima R et al. Interleukin-18 induces retinal pigment epithelium degeneration in mice. InveVis Sci. 55, 6673-8 (2014),
  3. Shen J et al. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF. J Cell Physiol. 229, 974-83 (2014)
  4. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012;209(13):2351-65.
  5. Souza-fonseca-guimaraes F, Parlato M, Fitting C, Cavaillon JM, Adib-conquy M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J Immunol. 2012;188(12):5850-8.
  6. Enoksson SL, Grasset EK, Hägglöf T, et al. The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells. Proc Natl Acad Sci USA. 2011;108(51):E1399-407.
  7. Nakahira M, Nakanishi K. Requirement of GATA-binding protein 3 for II13 gene expression in IL-18-stimulated Th1 cells. Int Immunol. 2011;23(12):761-72.
  8. Ghose P, Ali AQ, Fang R, Forbes D, Ballard B, Ismail N. The interaction between IL-18 and IL-18 receptor limits the magnitude of protective immunity and enhances pathogenic responses following infection with intracellular bacteria. J Immunol. 2011;187(3):1333-46.
  9. Kinoshita M, Miyazaki H, Ono S, et al. Enhancement of neutrophil function by interleukin-18 therapy protects burn-injured mice from methicillin-resistant Staphylococcus aureus. Infect Immun. 2011;79(7):2670-80.
  10. Segawa S, Goto D, Yoshiga Y, et al. Involvement of NK 1.1-positive γδT cells in interleukin-18 plus interleukin-2-induced interstitial lung disease. Am J Respir Cell Mol Biol. 2011;45(3):659-66.
  11. Zaki MH, Vogel P, Body-malapel M, Lamkanfi M, Kanneganti TD. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010;185(8):4912-20.
  12. Kuroda-morimoto M, Tanaka H, Hayashi N, et al. Contribution of IL-18 to eosinophilic airway inflammation induced by immunization and challenge with Staphylococcus aureus proteins. Int Immunol. 2010;22(7):561-70.
  13. Humann J, Lenz LL. Activation of naive NK cells in response to Listeria monocytogenes requires IL-18 and contact with infected dendritic cells. J Immunol. 2010;184(9):5172-8.
  14. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol. 2009;41(6):661-70.
  15. Hayashi N, Yoshimoto T, Izuhara K, Matsui K, Tanaka T, Nakanishi K. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 production. Proc Natl Acad Sci USA. 2007;104(37):14765-70.
  16. Zorrilla EP, Sanchez-alavez M, Sugama S, et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA. 2007;104(26):11097-102.
  17. Shui HA, Ka SM, Wu WM, et al. LPS-evoked IL-18 expression in mesangial cells plays a role in accelerating lupus nephritis. Rheumatology (Oxford). 2007;46(8):1277-84.
  18. Kuranaga N, Kinoshita M, Kawabata T, Habu Y, Shinomiya N, Seki S. Interleukin-18 protects splenectomized mice from lethal Streptococcus pneumoniae sepsis independent of interferon-gamma by inducing IgM production. J Infect Dis. 2006;194(7):993-1002.
  19. Ishikawa Y, Yoshimoto T, Nakanishi K. Contribution of IL-18-induced innate T cell activation to airway inflammation with mucus hypersecretion and airway hyperresponsiveness. Int Immunol. 2006;18(6):847-55.
  20. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res. 2006;12(2):643-52.
  21. Sasaki Y, Yoshimoto T, Maruyama H, et al. IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity. J Exp Med. 2005;202(5):607-16.
  22. Li Q, Carr AL, Donald EJ, et al. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 2005;65(3):1063-70.
  23. Beadling C, Slifka MK. Differential regulation of virus-specific T-cell effector functions following activation by peptide or innate cytokines. Blood. 2005;105(3):1179-86.
  24. Min CK, Maeda Y, Lowler K, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood. 2004;104(10):3393-9.
  25. Plitz T, Saint-mézard P, Satho M, et al. IL-18 binding protein protects against contact hypersensitivity. J Immunol. 2003;171(3):1164-71.
  26. Ito A, Matejuk A, Hopke C, et al. Transfer of severe experimental autoimmune encephalomyelitis by IL-12- and IL-18-potentiated T cells is estrogen sensitive. J Immunol. 2003;170(9):4802-9.
  27. Fukao T, Matsuda S, Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol. 2000;164(1):64-71.